REVIEW TAK-901 is a small-molecule inhibitor of the serine-threonine kinase Aurora B with potential antineoplastic activity. Aurora B is a positive regulator of mitosis that functions in the attachment of the mitotic spindle to the centromere. This serine/threonine kinase may be amplified and overexpressed by a variety of cancer cell types. After binding of TAK-901 to Aurora B, it inhibits the activity of Aurora B, which may result in a reduction in the proliferation of tumor cells that overexpress Aurora B. TAK-901 is originally developed by Millennium Pharmaceuticals, Inc.. And TAK-901 is been performed phase I clinical trials for the treatment of advanced solid tumors and lymphoma.
All products are stocked and shipped from the SF Bay, California, USA via FedEx, UPS or DHL.
All batches backed with full quality assurance.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
